TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants Without Objective Neuromuscular Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Function of leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Sebum Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlation between clinical suspicion and histological diagnosis of retained placental tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Ability to perform normal activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of clinically/radiologically confirmed pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of TB IRIS
Endpoint domain: Adverse events/effects
Primary endpoint: Change in frequency and duration of resident Resistiveness to Care behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barnes Akathisia rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative syndrome scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for the Assessment of Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Sign Score (TSS) in Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical Global Impression for Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Unified Parkinson's disease Rating Scale Part II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's disease Rating Scale Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 2-h Postprandial Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of pelvic collections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: At-risk drinking reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugl-Meyer motor assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with bhCG positive test after embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of patients with ongoing clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of live births after embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cure without recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Rates of Medically Attended Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Anaphylaxis and Urticaria
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of Hospitalizations and Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Discrimination of Alzheimer's Disease patients from healthy volunteers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of recovery from SAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV RNA <50c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 cells count >500 cells/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Surgical Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Free of Objective Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Toxicities of the Combination of Sirolimus and Erlotinib
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of NLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in logMAR Visual Acuity of Each Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Median Eye Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned hospital admission from any cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Compliance rate of patients to physicians prescription
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total incidence number of Major Adverse Cardiovascular Events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of Ambrisentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Ambrisentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcomes in new onset cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in hair cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Ratio of Controller Medication to Total Asthma Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biochemical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative complication
Endpoint domain: Adverse events/effects
Primary endpoint: feasibility of procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Operation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anti-cancer stem cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patients' compliance in performing the semiquantitative pregnancy test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Onset time of sensory block in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time of motor blockade in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of sensory block in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of motor block in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T cell response to hepatitis B antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of electromagnetic interference (EMI)
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of cholesteatoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving IGA Score of Cleared or Minimal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PASI 90 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiac Ejection Fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of clinically significant prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of HPV vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of Abatacept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veno-occlusive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Amount of postoperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: King's Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Broome Pelvic Muscle Exercise Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Three-day voiding diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: One-hour pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Suicidal Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Suicidal Ideation/Intent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Number of Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Identification of penumbra in ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Imaging Data Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lamazym antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of eyes with central macular thickness <300 microns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve for effect of PRC-4016
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration for effect of PRC-4016
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global improvement in self-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evaluation by SKAMP Combined, Attention, and Deportment Scales
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean of 24h systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Satisfaction With Group Sessions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute cardiac dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Weill-Cornell LINCL scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression based on change in MRI imaging parameter (% grey matter volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease progression based on change in MRI imaging parameter (% ventricular volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disease progression based on change in MRI imaging parameter (cortical apparent diffusion coefficient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Remission of Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported rates of vaginal sex
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Connors-3 Parent Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: requirement for endotracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Non-HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Lipoprotein(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in C-reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased risk of VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Severity of Poor Appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceleration data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orientation data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of inflammatory rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen saturation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart rate score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory rate score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood pressure score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD8 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Laboratory and clinical adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen Consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical resection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful PICC tip placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Implicit Time assessed by mfERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients With No or Minor Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Percentage of Patients With No Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Time Until Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response as per MADRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients with intracranial hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: myopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients Wearing Activity Monitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: maximum tolerated dose (MTD) of SAR566658
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preliminary anti-tumoral effect of SAR566658
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: effect on CYP3A enzyme activity using midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of the interferon-gamma release assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abstinence from benzodiazepine use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clearance (CL, mL/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the concentration-time curve (AUC0 ∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Syndecan-1 level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sVGEFR-2 level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in KIM-1 level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Interleukin-6 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraocular pressure-hypertensive phase success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiological reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: physiological reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in levels of serum total testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in levels of serum calculated free testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dosimetric study results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remaining wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EFT scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Patients Achieving Parathyroid Hormone Target ≤ 300
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent of Patients Achieving Phosphorous Target ≤ 5.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective response to everolimus after 6 months therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of prostaglandin E2 (PGE2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic pressure/diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood cytokine profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Markers concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of lung metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: neopterin levels in salivary and gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first analgesics catch per os
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of FDG-PET/CT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: quality of dying
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of multimodality MR Imaging in evaluating acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of bone and callus patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total cost of stem cell mobilization procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: New onset pulmonary edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cohen Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Centre for Epidemiologic Studies Depression Scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stroke Impact Scale (SIS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short-Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of NASH without worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver-related outcomes
Primary endpoint: Cardiovascular and liver-related death events
Endpoint domain: Mortality/survival
Primary endpoint: Ilaprazole AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ilaprazole Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clarithromycin, Amoxicillin AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clarithromycin, Amoxicillin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterozygosity for Filaggrin (FLG) Null Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Characteristics of parasympathetic (vagal) heart regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characteristics of sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain quality assessment using Neonatal Facial Coding System (NFCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes